Related Experiment Video
Updated: Feb 22, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond
Garrick C Stewart1, Amrut V Ambardekar2, Michelle M Kittleson3
1Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115, USA. gcstewart@bwh.harvard.edu.
Left Ventricular Assist Devices (LVADs) offer extended survival for advanced heart failure (HF) patients. Appropriately selected ambulatory patients, even those not critically ill, may benefit from LVADs after careful risk-benefit assessment.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Extended survival with Left Ventricular Assist Devices (LVADs) has increased interest in their use for ambulatory patients with advanced heart failure (HF).
- Current limitations exist in defining indications for LVAD implantation in less critically ill advanced HF patients.
Purpose of the Study:
- To review current understanding and decision-making for LVAD implantation in ambulatory advanced HF patients.
- To explore the prognostic information and decision-making guidance from studies like MedaMACS and ROADMAP.
- To highlight the need for individualized risk-benefit assessments beyond survival for LVAD candidates.
Main Methods:
- Review of findings from the MedaMACS and ROADMAP studies.
- Analysis of prognostic indicators and patient profiles (e.g., INTERMACS profiles) in advanced HF.
- Discussion of shared decision-making principles for LVAD therapy.
Main Results:
- Sicker INTERMACS profiles correlate with a higher risk of death or requiring a rescue LVAD.
- Ambulatory patients in INTERMACS profile 4 may be suitable candidates for LVADs due to high mortality and poor quality of life.
- Studies reveal discrepancies in perceived HF severity between patients and physicians.
Conclusions:
- LVADs can be considered for carefully selected ambulatory advanced HF patients, particularly those in INTERMACS profile 4.
- Shared decision-making is crucial, involving a nuanced evaluation of risks and benefits beyond mere survival.
- Future research, including the REVIVAL study, will further inform prognostic understanding and guide complex LVAD therapy decisions.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy